Molecular Biology of the Cell Sign up for new MBC in Press e-TOCs!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E05-09-0875 on February 22, 2006

Vol. 17, Issue 5, 2243-2255, May 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Material
Right arrow All Versions of this Article:
E05-09-0875v1
17/5/2243    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Apaja, P. M.
Right arrow Articles by Petäjä-Repo, U. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apaja, P. M.
Right arrow Articles by Petäjä-Repo, U. E.

Luteinizing Hormone Receptor Ectodomain Splice Variant Misroutes the Full-Length Receptor into a Subcompartment of the Endoplasmic ReticulumFormula

Pirjo M. Apaja * {dagger}, Jussi T. Tuusa * {dagger}, E. Maritta Pietilä * {dagger}, Hannu J. Rajaniemi {dagger} {ddagger}, and Ulla E. Petäjä-Repo * {dagger} {ddagger}

* Biocenter Oulu, University of Oulu, FI-90014 Oulu, Finland; {dagger} Department of Anatomy and Cell Biology, University of Oulu, FI-90014 Oulu, Finland

Submitted September 20, 2005; Revised February 6, 2006; Accepted February 13, 2006
Monitoring Editor: Jeffrey Brodsky

The luteinizing hormone receptor (LHR) is a G protein–coupled receptor that is expressed in multiple RNA messenger forms. The common rat ectodomain splice variant is expressed concomitantly with the full-length LHR in tissues and is a truncated transcript corresponding to the partial ectodomain with a unique C-terminal end. Here we demonstrate that the variant alters the behavior of the full-length receptor by misrouting it away from the normal secretory pathway in human embryonic kidney 293 cells. The variant was expressed as two soluble forms of Mr 52,000 and Mr 54,000, but although the protein contains a cleavable signal sequence, no secretion to the medium was observed. Only a very small fraction of the protein was able to gain hormone-binding ability, suggesting that it is retained in the endoplasmic reticulum (ER) by its quality control due to misfolding. This was supported by the finding that the variant was found to interact with calnexin and calreticulin and accumulated together with these ER chaperones in a specialized juxtanuclear subcompartment of the ER. Only proteasomal blockade with lactacystin led to accumulation of the variant in the cytosol. Importantly, coexpression of the variant with the full-length LHR resulted in reduction in the number of receptors that were capable of hormone binding and were expressed at the cell surface and in targeting of immature receptors to the juxtanuclear ER subcompartment. Thus, the variant mediated misrouting of the newly synthesized full-length LHRs may provide a way to regulate the number of cell surface receptors.


This article was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E05–09–0875) on February 22, 2006.

Abbreviations used: BSA, bovine serum albumin; CG, chorionic gonadotropin; DDM; n-dodecyl-beta-D-maltoside; Endo H, endo-beta-N-acetylglucosaminidase H; ER, endoplasmic reticulum; ERAD, ER-associated degradation; GPCR, G protein–coupled receptor; HA, haemagglutinin; HEK293, human embryonic kidney 293; LH, luteinizing hormone; µOR, µ opioid receptor; PNGase F, peptide-N-glycosidase F; R, receptor; STI, soybean trypsin inhibitor; UPR, unfolded protein response.

Formula The online version of this article contains supplemental material at MBC Online (http://www.molbiolcell.org).

{ddagger} These authors contributed equally to this work.

Address correspondence to: Ulla Petäjä-Repo (Ulla.Petaja-Repo{at}oulu.fi) or Hannu Rajaniemi (Hannu.Rajaniemi{at}oulu.fi).




This article has been cited by other articles:


Home page
EndocrinologyHome page
A. Kern, D. Hubbard, A. Amano, and G. D. Bryant-Greenwood
Cloning, Expression, and Functional Characterization of Relaxin Receptor (Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 7) Splice Variants from Human Fetal Membranes
Endocrinology, March 1, 2008; 149(3): 1277 - 1294.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. T. Leskela, P. M. H. Markkanen, E. M. Pietila, J. T. Tuusa, and U. E. Petaja-Repo
Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum
J. Biol. Chem., August 10, 2007; 282(32): 23171 - 23183.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
S. K. Shenoy
Seven-Transmembrane Receptors and Ubiquitination
Circ. Res., April 27, 2007; 100(8): 1142 - 1154.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
U. E. Petaja-Repo, M. Hogue, T. T. Leskela, P. M. H. Markkanen, J. T. Tuusa, and M. Bouvier
Distinct Subcellular Localization for Constitutive and Agonist-modulated Palmitoylation of the Human {delta} Opioid Receptor
J. Biol. Chem., June 9, 2006; 281(23): 15780 - 15789.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2006 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.